Xiaoxu Li, Laboratory of Integrative Systems Physiology, Lausanne, Switzerland, considers the potential of LXR inhibition with the liver and gut restricted inverse agonist, TLC-2716, in the treatment of dyslipidaemia and metabolic dysfunction-associated steatotic liver disease.
Please login or create a FREE account to view this content
Educational Supporters of the 12th Closed Scientific Expert Meeting of the Editorial Board
Principal supporters:
Guest supporters:
